My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    LDE225 (NVP-LDE225,Erismodegib)
    LDE225 (NVP-LDE225,Erismodegib)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1333
    CAS #: 956697-53-3 (free base)Purity ≥98%

    Description: Erismodegib (formerly LDE-225; NVP LDE-225; LDE225; NVP-LDE22; Sonidegib; trade name of Odomzo) is an orally bioavailable small-molecule antagonist of the Smoothened (Smo) in Hedgehog signaling pathway with potential antitumor activity. It inhibits the Hedgehog (Hh) signaling with an IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. As an approved anticancer medication, LDE225 (NVP-LDE225, Erismodegib, Sonidegib) specifically binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, resulting in the suppression of the Hedgehog signaling pathway and thus the inhibition of tumor cell growth in which the Hedgehog pathway is abnormally activated. It is an anticancer drug that received FDA approval in 2015 for the treatment of basal cell carcinoma. 

    References: Ann Surg. 2011 Nov;254(5):818-23;  ACS Med. Chem. Lett., 2010, 1 (3), 130–134.

    Related CAS #: 1218778-77-8 (phosphate); 1799493-22-3 (Sonidegib metabolite M25)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)485.5
    FormulaC26H26F3N3O3
    CAS No.956697-53-3 (free base); 1218778-77-8 (phosphate)
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 97 mg/mL (199.8 mM)
    Water:<1 mg/mL
    Ethanol: 97 mg/mL (199.8 mM)
    Solubility (In vivo)2% DMSO+corn oil: 10 mg/mL  
    SynonymsSonidegib; LDE 225; NVP-LDE225; LDE-225; NVP LDE-225; LDE225; NVP LDE225; Erismodegib; trade name of Odomzo


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: LDE225 (also known as NVP-LDE225, Erismodegib, Sonidegib; trade name of Odomzo) is an orally bioavailable small-molecule antagonist of the Smoothened (Smo) which inhibits the Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. LDE225 (NVP-LDE225, Erismodegib, Sonidegib) specifically binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, resulting in the suppression of the Hedgehog signaling pathway and thus the inhibition of tumor cell growth in which the Hedgehog pathway is abnormally activated. It is an anticancer drug that received FDA approval in 2015 for the treatment of basal cell carcinoma.


    Kinase Assay:   LDE225 inhibits TM3 luciferized cell line with 0.6 nM and 8 nM, at the presence of 1 nM and 25 nM Hh agonist Ag1.5, respectively.


    Cell Assay: LDE225 induced apoptosis in a dose-dependent manner. Treatment of prostate CSCs resulted in an increase in the expression of cleaved caspase-3 and PARP. LDE225 inhibited cell viability in primary and secondary spheroids in a dose-dependent manner.

    In VivoLDE225 is highly bound to mouse, rat, and human plasma proteins (>99%) and moderately bound to dog and monkey plasma proteins (77 and 85%, respectively). LDE225 has high permeability (90.8% in man) in the PAMPA assay. LDE225 shows good oral bioavailability ranging from 69 to 102% in preclinical species when dosed in solution. LDE225 is a weak base with a measured pKa of 4.20 and exhibits relatively poor aqueous solubility. LDE225 demonstrates dose-related antitumor activity. At a dose of 5 mg/kg/day qd, LDE225 significantly inhibits tumor growth, corresponding to a T/C value of 33%. When dosed at 10 and 20 mg/kg/day qd, LDE225 gives rise to 51 and 83% regression, respectively. Gli1 mRNA inhibition correlates with tumor and plasma exposure of LDE225. LDE225 successfully penetrates the blood−brain barrier in tumor-bearing animals and results in tumor growth inhibition after 4 days of treatment. LDE225 significantly reduces the tumor volume by 95.7% in Rip1-Tag2 mice. LDE225 prolongs survival in Rip1Tag2 mice. LDE225 decreases expression of stromal markers in the LDE225-treated mice.
    Animal modelOrthotopic Ptch+/-p53-/- medulloblastoma allograft model in athymic nude mice
    Formulation & DosageDissolved in 0.5% sodium carboxymethyl cellulose, and diluted in saline; 40 mg/kg; Oral administration
    ReferencesAnn Surg. 2011 Nov;254(5):818-23;  ACS Med. Chem. Lett., 2010, 1 (3), 130–134.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    LDE225 (Sonidegib)

    Antitumor activity in an orthotopic Ptch+/−p53−/− medulloblastoma allograft model in nude mice upon treatment with 5mdiphosphate salt dosed at 40 mg/kg/day po bid or vehicle at equal dose volume.  . 2010 Jun 10; 1(3): 130–134.

    LDE225 (Sonidegib)

    Antitumor activity upon treatment with 5m diphosphate salt or vehicle in a Ptch+/−p53−/−  medulloblastoma  subcutaneous allograft model in nude mice. . 2010 Jun 10; 1(3): 130–134.

     

    LDE225 (Sonidegib)

    Gli1 mRNA inhibition (open circle), tumor PK (filled squares), and plasma PK (filled triangles) in Ptch+/−p53−/− medulloblastoma model after treatment with 5m (Sonidegib, or erismodegib, LDE225, NVP-LDE225). . 2010 Jun 10; 1(3): 130–134.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?